 Lorna Moore
Concepts (441)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 79 | 2023 | 422 | 14.580 |
Why?
| | Uterine Artery | 15 | 2022 | 65 | 5.540 |
Why?
| | Fetal Growth Retardation | 29 | 2023 | 468 | 5.090 |
Why?
| | Pre-Eclampsia | 16 | 2023 | 183 | 4.880 |
Why?
| | Hypoxia | 35 | 2023 | 963 | 4.210 |
Why?
| | Acclimatization | 20 | 2019 | 135 | 3.690 |
Why?
| | Pregnancy | 71 | 2023 | 5691 | 3.660 |
Why?
| | Fetal Hypoxia | 11 | 2022 | 46 | 3.550 |
Why?
| | Uterus | 14 | 2020 | 194 | 3.400 |
Why?
| | Altitude Sickness | 18 | 2022 | 163 | 2.920 |
Why?
| | Placenta | 15 | 2023 | 639 | 2.490 |
Why?
| | Placental Circulation | 8 | 2022 | 56 | 2.370 |
Why?
| | Birth Weight | 22 | 2019 | 465 | 2.280 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2023 | 46 | 2.190 |
Why?
| | Oxygen | 17 | 2023 | 854 | 2.140 |
Why?
| | Adaptation, Physiological | 12 | 2021 | 502 | 2.010 |
Why?
| | Vasodilation | 9 | 2022 | 457 | 1.990 |
Why?
| | Arteries | 9 | 2022 | 250 | 1.940 |
Why?
| | Fetal Development | 8 | 2022 | 250 | 1.910 |
Why?
| | Bolivia | 19 | 2023 | 60 | 1.780 |
Why?
| | AMP-Activated Protein Kinases | 6 | 2023 | 178 | 1.370 |
Why?
| | Vasoconstriction | 4 | 2015 | 213 | 1.370 |
Why?
| | Regional Blood Flow | 9 | 2015 | 418 | 1.200 |
Why?
| | Selection, Genetic | 8 | 2019 | 252 | 1.160 |
Why?
| | Myometrium | 2 | 2020 | 35 | 1.150 |
Why?
| | Female | 95 | 2023 | 61565 | 1.110 |
Why?
| | Nitric Oxide Synthase | 3 | 2019 | 225 | 1.100 |
Why?
| | Fertility | 2 | 2021 | 135 | 1.050 |
Why?
| | Oxygen Consumption | 15 | 2012 | 586 | 1.030 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 907 | 0.990 |
Why?
| | HELLP Syndrome | 1 | 2023 | 6 | 0.950 |
Why?
| | Biological Evolution | 5 | 2015 | 443 | 0.930 |
Why?
| | Tibet | 14 | 2021 | 28 | 0.840 |
Why?
| | Pregnancy, Animal | 4 | 2006 | 57 | 0.800 |
Why?
| | Adult | 56 | 2021 | 31512 | 0.800 |
Why?
| | Exercise | 8 | 2018 | 1657 | 0.790 |
Why?
| | Vascular Resistance | 6 | 2020 | 356 | 0.790 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2019 | 454 | 0.780 |
Why?
| | Hemoglobins | 8 | 2017 | 326 | 0.770 |
Why?
| | Humans | 101 | 2023 | 118974 | 0.760 |
Why?
| | Pregnancy Outcome | 4 | 2019 | 349 | 0.750 |
Why?
| | Hemodynamics | 8 | 2021 | 1004 | 0.740 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.730 |
Why?
| | Adrenergic alpha-Antagonists | 4 | 2003 | 31 | 0.700 |
Why?
| | Pregnancy Complications | 6 | 2017 | 448 | 0.690 |
Why?
| | Infant, Newborn | 21 | 2022 | 5255 | 0.690 |
Why?
| | Polycythemia | 3 | 2017 | 26 | 0.680 |
Why?
| | Maternal-Fetal Exchange | 4 | 2021 | 157 | 0.660 |
Why?
| | Protein Kinases | 1 | 2020 | 310 | 0.640 |
Why?
| | Maternal Health Services | 1 | 2019 | 83 | 0.620 |
Why?
| | Catecholamines | 8 | 2003 | 100 | 0.580 |
Why?
| | Menstrual Cycle | 7 | 2003 | 113 | 0.560 |
Why?
| | Women's Health | 2 | 2011 | 274 | 0.550 |
Why?
| | Gestational Age | 9 | 2021 | 765 | 0.550 |
Why?
| | Infant, Small for Gestational Age | 3 | 2011 | 73 | 0.550 |
Why?
| | Fetus | 5 | 2023 | 690 | 0.510 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 60 | 0.490 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 284 | 0.490 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 424 | 0.490 |
Why?
| | Aromatase | 1 | 2014 | 31 | 0.490 |
Why?
| | Genetics, Population | 6 | 2010 | 207 | 0.470 |
Why?
| | Blood Pressure | 11 | 2020 | 1664 | 0.460 |
Why?
| | Endothelin-1 | 2 | 2020 | 168 | 0.450 |
Why?
| | Ultrasonography, Doppler | 3 | 2020 | 104 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 10 | 2019 | 2062 | 0.440 |
Why?
| | Health Services Accessibility | 1 | 2019 | 781 | 0.440 |
Why?
| | Indians, South American | 6 | 2015 | 23 | 0.440 |
Why?
| | Respiratory Mechanics | 4 | 2007 | 60 | 0.430 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 61 | 0.430 |
Why?
| | Estrogens | 2 | 2014 | 328 | 0.430 |
Why?
| | Phenylephrine | 6 | 2020 | 85 | 0.430 |
Why?
| | PPAR gamma | 3 | 2020 | 188 | 0.430 |
Why?
| | Infant, Low Birth Weight | 2 | 2011 | 125 | 0.420 |
Why?
| | Angiotensin II | 2 | 2011 | 107 | 0.420 |
Why?
| | Sleep Apnea Syndromes | 1 | 2013 | 80 | 0.420 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2011 | 8 | 0.400 |
Why?
| | Gene Frequency | 5 | 2014 | 513 | 0.400 |
Why?
| | Travel | 1 | 2012 | 116 | 0.400 |
Why?
| | Enzymes | 1 | 2011 | 66 | 0.400 |
Why?
| | Genome, Human | 4 | 2012 | 387 | 0.400 |
Why?
| | Homeostasis | 2 | 2014 | 594 | 0.390 |
Why?
| | Prazosin | 5 | 2003 | 22 | 0.380 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 5 | 0.380 |
Why?
| | Infant Mortality | 2 | 2021 | 94 | 0.380 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 21 | 0.380 |
Why?
| | Nitric Oxide | 3 | 2020 | 892 | 0.380 |
Why?
| | South America | 5 | 2017 | 56 | 0.370 |
Why?
| | Animals | 22 | 2023 | 33381 | 0.360 |
Why?
| | Young Adult | 10 | 2020 | 10793 | 0.340 |
Why?
| | Interleukin-1beta | 1 | 2010 | 379 | 0.320 |
Why?
| | Mountaineering | 2 | 2005 | 47 | 0.320 |
Why?
| | Guinea Pigs | 6 | 2006 | 151 | 0.310 |
Why?
| | Antioxidants | 1 | 2011 | 564 | 0.310 |
Why?
| | Heart Rate | 7 | 2015 | 729 | 0.310 |
Why?
| | Europe | 4 | 2009 | 356 | 0.290 |
Why?
| | Oxidative Stress | 1 | 2013 | 1178 | 0.280 |
Why?
| | Case-Control Studies | 5 | 2017 | 3171 | 0.270 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2005 | 40 | 0.270 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 66 | 0.270 |
Why?
| | Acetylcholine | 2 | 2020 | 208 | 0.270 |
Why?
| | Fetal Death | 2 | 2003 | 52 | 0.260 |
Why?
| | Research | 2 | 2005 | 411 | 0.260 |
Why?
| | Infant | 6 | 2021 | 8293 | 0.250 |
Why?
| | Cytokines | 2 | 2010 | 1900 | 0.250 |
Why?
| | Placental Insufficiency | 2 | 2023 | 104 | 0.250 |
Why?
| | Mice | 8 | 2021 | 15520 | 0.240 |
Why?
| | Embryonic and Fetal Development | 2 | 2003 | 95 | 0.240 |
Why?
| | Norepinephrine | 3 | 2001 | 212 | 0.240 |
Why?
| | Peru | 2 | 2021 | 59 | 0.240 |
Why?
| | Mammals | 2 | 2022 | 253 | 0.240 |
Why?
| | Epinephrine | 3 | 2001 | 167 | 0.240 |
Why?
| | Blood Flow Velocity | 3 | 2011 | 327 | 0.240 |
Why?
| | Chi-Square Distribution | 2 | 2018 | 525 | 0.240 |
Why?
| | Parity | 2 | 2018 | 101 | 0.240 |
Why?
| | Models, Genetic | 2 | 2007 | 595 | 0.240 |
Why?
| | Chronic Disease | 7 | 2013 | 1636 | 0.230 |
Why?
| | Interleukin-6 | 2 | 2010 | 688 | 0.230 |
Why?
| | Mining | 1 | 2003 | 16 | 0.230 |
Why?
| | Silver | 1 | 2003 | 27 | 0.220 |
Why?
| | Amino Acids | 3 | 2023 | 465 | 0.220 |
Why?
| | Speech Production Measurement | 1 | 2002 | 15 | 0.220 |
Why?
| | Receptors, Adrenergic, alpha-1 | 2 | 2001 | 40 | 0.220 |
Why?
| | Geography | 3 | 2011 | 190 | 0.220 |
Why?
| | Speech Disorders | 1 | 2002 | 35 | 0.220 |
Why?
| | Carbohydrate Metabolism | 2 | 2000 | 50 | 0.210 |
Why?
| | Regression Analysis | 3 | 2018 | 983 | 0.210 |
Why?
| | Myoglobin | 1 | 2002 | 15 | 0.210 |
Why?
| | Progesterone | 5 | 2003 | 242 | 0.210 |
Why?
| | Erythropoiesis | 1 | 2001 | 33 | 0.210 |
Why?
| | Potassium Channels | 2 | 2022 | 123 | 0.210 |
Why?
| | Trophoblasts | 2 | 2019 | 170 | 0.210 |
Why?
| | Developing Countries | 1 | 2023 | 255 | 0.210 |
Why?
| | Motor Skills | 1 | 2002 | 85 | 0.200 |
Why?
| | Adrenergic alpha-Agonists | 4 | 2003 | 31 | 0.200 |
Why?
| | Male | 26 | 2019 | 57801 | 0.200 |
Why?
| | Reproduction | 1 | 2003 | 189 | 0.200 |
Why?
| | Glycolysis | 2 | 2021 | 224 | 0.200 |
Why?
| | Gene Expression Regulation | 4 | 2021 | 2445 | 0.190 |
Why?
| | Luteal Phase | 5 | 2001 | 44 | 0.190 |
Why?
| | Pyrones | 1 | 2020 | 9 | 0.190 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2020 | 11 | 0.190 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2000 | 31 | 0.190 |
Why?
| | Ribonucleotides | 1 | 2020 | 26 | 0.190 |
Why?
| | Muscle Relaxation | 1 | 2000 | 32 | 0.190 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 104 | 0.190 |
Why?
| | Reproductive Health | 1 | 2021 | 68 | 0.180 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 4908 | 0.180 |
Why?
| | Biphenyl Compounds | 1 | 2020 | 52 | 0.180 |
Why?
| | Risk Factors | 5 | 2019 | 9000 | 0.180 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1794 | 0.180 |
Why?
| | Arterial Pressure | 2 | 2017 | 99 | 0.180 |
Why?
| | Genotype | 4 | 2014 | 1882 | 0.180 |
Why?
| | Respiratory Function Tests | 3 | 2013 | 526 | 0.180 |
Why?
| | Genetic Markers | 3 | 2012 | 348 | 0.180 |
Why?
| | Thiophenes | 1 | 2020 | 106 | 0.180 |
Why?
| | Erythropoietin | 2 | 2017 | 82 | 0.180 |
Why?
| | Vasoconstrictor Agents | 1 | 2020 | 122 | 0.180 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 181 | 0.170 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 2 | 2017 | 20 | 0.170 |
Why?
| | Biological Transport | 3 | 2019 | 382 | 0.170 |
Why?
| | Blood Volume | 4 | 2007 | 58 | 0.170 |
Why?
| | Blood Gas Analysis | 3 | 2007 | 69 | 0.170 |
Why?
| | Estradiol | 5 | 2003 | 476 | 0.170 |
Why?
| | Follicular Phase | 5 | 2001 | 41 | 0.170 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 301 | 0.170 |
Why?
| | Glyburide | 1 | 1998 | 36 | 0.160 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 35 | 0.160 |
Why?
| | Intraocular Pressure | 1 | 2000 | 275 | 0.160 |
Why?
| | Health Promotion | 1 | 2005 | 691 | 0.160 |
Why?
| | Delivery, Obstetric | 2 | 2011 | 125 | 0.160 |
Why?
| | Sudden Infant Death | 1 | 1998 | 25 | 0.160 |
Why?
| | Maternal Age | 1 | 2018 | 122 | 0.160 |
Why?
| | Body Weights and Measures | 2 | 2015 | 35 | 0.160 |
Why?
| | Cohort Studies | 4 | 2020 | 5116 | 0.160 |
Why?
| | Analysis of Variance | 3 | 2011 | 1293 | 0.160 |
Why?
| | Vasodilator Agents | 1 | 2020 | 328 | 0.160 |
Why?
| | Ethiopia | 1 | 2017 | 35 | 0.160 |
Why?
| | Respiration | 3 | 2005 | 183 | 0.160 |
Why?
| | Physical Endurance | 2 | 2001 | 231 | 0.150 |
Why?
| | DNA | 2 | 2006 | 1388 | 0.150 |
Why?
| | Glucose | 2 | 2023 | 953 | 0.150 |
Why?
| | Ovariectomy | 1 | 1997 | 124 | 0.150 |
Why?
| | Models, Biological | 4 | 2015 | 1715 | 0.150 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 25 | 0.150 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 25 | 0.150 |
Why?
| | Vascular Diseases | 2 | 2017 | 241 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2022 | 67 | 0.140 |
Why?
| | Linear Models | 2 | 2014 | 827 | 0.140 |
Why?
| | Pulmonary Gas Exchange | 2 | 2015 | 117 | 0.140 |
Why?
| | Time Factors | 8 | 2011 | 6412 | 0.140 |
Why?
| | Cardiovascular System | 1 | 2017 | 127 | 0.140 |
Why?
| | Pregnancy Complications, Cardiovascular | 3 | 2007 | 70 | 0.140 |
Why?
| | Adolescent | 5 | 2019 | 18480 | 0.140 |
Why?
| | Lipid Metabolism | 1 | 2018 | 477 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2023 | 527 | 0.130 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 219 | 0.130 |
Why?
| | Electrocardiography | 1 | 1998 | 556 | 0.130 |
Why?
| | Double-Blind Method | 4 | 2003 | 1687 | 0.130 |
Why?
| | Incidence | 2 | 2018 | 2424 | 0.130 |
Why?
| | Retrospective Studies | 4 | 2022 | 12978 | 0.130 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1474 | 0.120 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 198 | 0.120 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 53 | 0.120 |
Why?
| | Polymorphism, Genetic | 2 | 2012 | 642 | 0.120 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2674 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 4552 | 0.120 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 49 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2021 | 468 | 0.120 |
Why?
| | In Vitro Techniques | 2 | 2011 | 1094 | 0.120 |
Why?
| | Sex Characteristics | 5 | 2001 | 671 | 0.120 |
Why?
| | Phenotype | 2 | 2023 | 3003 | 0.120 |
Why?
| | Body Height | 2 | 2013 | 187 | 0.120 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 827 | 0.110 |
Why?
| | Body Weight | 3 | 2007 | 934 | 0.110 |
Why?
| | Ultrasonography, Prenatal | 2 | 2013 | 227 | 0.110 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 122 | 0.110 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 239 | 0.110 |
Why?
| | Pregnancy Trimesters | 1 | 2012 | 13 | 0.110 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2012 | 48 | 0.110 |
Why?
| | Optic Atrophy, Hereditary, Leber | 1 | 2012 | 4 | 0.110 |
Why?
| | Hypertension | 3 | 2015 | 1203 | 0.110 |
Why?
| | Pulmonary Artery | 2 | 2015 | 1063 | 0.110 |
Why?
| | Indomethacin | 1 | 2012 | 75 | 0.110 |
Why?
| | NADH Dehydrogenase | 1 | 2012 | 18 | 0.110 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2012 | 72 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2014 | 371 | 0.110 |
Why?
| | Polysomnography | 1 | 2013 | 157 | 0.110 |
Why?
| | Reference Values | 4 | 2003 | 774 | 0.110 |
Why?
| | Prevalence | 1 | 2018 | 2326 | 0.110 |
Why?
| | Lactic Acid | 3 | 2023 | 282 | 0.100 |
Why?
| | Age Factors | 2 | 2011 | 2995 | 0.100 |
Why?
| | Colorado | 5 | 2019 | 4196 | 0.100 |
Why?
| | Middle Aged | 5 | 2019 | 27617 | 0.100 |
Why?
| | Apgar Score | 1 | 2011 | 16 | 0.100 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 369 | 0.100 |
Why?
| | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2011 | 4 | 0.100 |
Why?
| | Potassium Chloride | 1 | 2011 | 41 | 0.100 |
Why?
| | Atmospheric Pressure | 2 | 2001 | 19 | 0.100 |
Why?
| | Population Dynamics | 1 | 2012 | 137 | 0.100 |
Why?
| | DNA Methylation | 1 | 2015 | 503 | 0.100 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 33 | 0.100 |
Why?
| | Live Birth | 1 | 2011 | 47 | 0.100 |
Why?
| | Iliac Artery | 1 | 2011 | 44 | 0.100 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 187 | 0.100 |
Why?
| | Stillbirth | 1 | 2011 | 57 | 0.100 |
Why?
| | Signal Transduction | 2 | 2021 | 4709 | 0.100 |
Why?
| | Child Development | 1 | 2015 | 410 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2011 | 324 | 0.090 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 38 | 0.090 |
Why?
| | Alleles | 3 | 2012 | 832 | 0.090 |
Why?
| | Sympathetic Nervous System | 2 | 2003 | 171 | 0.090 |
Why?
| | Haplotypes | 3 | 2017 | 473 | 0.090 |
Why?
| | Renal Circulation | 3 | 1998 | 75 | 0.090 |
Why?
| | Anthropology, Physical | 1 | 2009 | 29 | 0.090 |
Why?
| | Ultrasonography | 1 | 2014 | 716 | 0.090 |
Why?
| | Sheep | 2 | 2023 | 764 | 0.090 |
Why?
| | Genomics | 2 | 2023 | 706 | 0.090 |
Why?
| | Mesenteric Arteries | 2 | 2000 | 16 | 0.090 |
Why?
| | Interleukin-4 | 1 | 2010 | 215 | 0.090 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 256 | 0.090 |
Why?
| | Pedigree | 1 | 2010 | 485 | 0.090 |
Why?
| | Databases, Genetic | 1 | 2010 | 253 | 0.080 |
Why?
| | Lung Diseases | 1 | 2015 | 718 | 0.080 |
Why?
| | Ovary | 2 | 2018 | 205 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2010 | 306 | 0.080 |
Why?
| | Exercise Test | 3 | 2001 | 551 | 0.080 |
Why?
| | Up-Regulation | 1 | 2011 | 872 | 0.080 |
Why?
| | Basal Metabolism | 3 | 2003 | 50 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1323 | 0.080 |
Why?
| | Lung | 1 | 2021 | 3664 | 0.080 |
Why?
| | Prospective Studies | 3 | 2022 | 6471 | 0.080 |
Why?
| | Head | 1 | 2008 | 89 | 0.080 |
Why?
| | Heart Rate, Fetal | 1 | 2007 | 22 | 0.080 |
Why?
| | Premature Birth | 1 | 2011 | 284 | 0.080 |
Why?
| | Biometry | 1 | 2007 | 65 | 0.070 |
Why?
| | Aorta, Thoracic | 2 | 2000 | 248 | 0.070 |
Why?
| | Urban Health | 1 | 2007 | 78 | 0.070 |
Why?
| | Femur | 1 | 2008 | 199 | 0.070 |
Why?
| | Indians, North American | 2 | 2009 | 598 | 0.070 |
Why?
| | Health Status | 1 | 2011 | 726 | 0.070 |
Why?
| | Phylogeny | 2 | 2010 | 816 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3730 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2007 | 510 | 0.070 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2007 | 101 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2513 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2006 | 64 | 0.070 |
Why?
| | Serum | 1 | 2006 | 63 | 0.070 |
Why?
| | Mental Health | 1 | 2011 | 568 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 4708 | 0.070 |
Why?
| | Hyperplasia | 1 | 2006 | 170 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1171 | 0.070 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2001 | 16 | 0.070 |
Why?
| | Cell Count | 1 | 2006 | 315 | 0.070 |
Why?
| | History, 21st Century | 1 | 2005 | 170 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2275 | 0.060 |
Why?
| | History, 20th Century | 1 | 2005 | 281 | 0.060 |
Why?
| | Child | 4 | 2015 | 19129 | 0.060 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 201 | 0.060 |
Why?
| | Plasma Volume | 1 | 2003 | 13 | 0.060 |
Why?
| | Cardiac Output | 3 | 1998 | 147 | 0.060 |
Why?
| | Lower Extremity | 1 | 2007 | 335 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1597 | 0.060 |
Why?
| | Pyruvates | 1 | 2023 | 20 | 0.060 |
Why?
| | Embryo Implantation | 1 | 2003 | 24 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 246 | 0.060 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 683 | 0.060 |
Why?
| | Acute Disease | 2 | 2005 | 940 | 0.060 |
Why?
| | History, 17th Century | 1 | 2003 | 18 | 0.060 |
Why?
| | Primary Prevention | 1 | 2005 | 185 | 0.060 |
Why?
| | Ion Channels | 1 | 2023 | 126 | 0.060 |
Why?
| | Glutamine | 1 | 2023 | 88 | 0.060 |
Why?
| | Sound Spectrography | 1 | 2002 | 24 | 0.050 |
Why?
| | Speech Acoustics | 1 | 2002 | 11 | 0.050 |
Why?
| | Serine | 1 | 2023 | 138 | 0.050 |
Why?
| | Ischemia | 1 | 2006 | 374 | 0.050 |
Why?
| | Locomotion | 1 | 2003 | 83 | 0.050 |
Why?
| | Blood Glucose | 3 | 2001 | 1939 | 0.050 |
Why?
| | Glycine | 1 | 2023 | 162 | 0.050 |
Why?
| | Muscle Fatigue | 2 | 2001 | 91 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 67 | 0.050 |
Why?
| | Cesarean Section | 1 | 2023 | 165 | 0.050 |
Why?
| | Partial Pressure | 1 | 2001 | 29 | 0.050 |
Why?
| | Anaerobic Threshold | 1 | 2001 | 21 | 0.050 |
Why?
| | Health Education | 1 | 2005 | 318 | 0.050 |
Why?
| | C-Peptide | 2 | 2001 | 137 | 0.050 |
Why?
| | Insulin | 3 | 2001 | 2162 | 0.050 |
Why?
| | Species Specificity | 1 | 2003 | 565 | 0.050 |
Why?
| | Veins | 1 | 2001 | 60 | 0.050 |
Why?
| | Plethysmography | 1 | 2001 | 124 | 0.050 |
Why?
| | Pyruvic Acid | 1 | 2021 | 48 | 0.050 |
Why?
| | Forearm | 1 | 2001 | 117 | 0.050 |
Why?
| | Disease Susceptibility | 1 | 2003 | 331 | 0.050 |
Why?
| | Ventricular Pressure | 1 | 2021 | 41 | 0.050 |
Why?
| | Exons | 1 | 2002 | 307 | 0.050 |
Why?
| | Muscle, Skeletal | 2 | 2001 | 1515 | 0.050 |
Why?
| | Hyperbaric Oxygenation | 1 | 2021 | 39 | 0.050 |
Why?
| | Risk Assessment | 1 | 2010 | 3057 | 0.050 |
Why?
| | Posture | 1 | 2001 | 158 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2002 | 456 | 0.050 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.050 |
Why?
| | Asia | 1 | 2000 | 54 | 0.050 |
Why?
| | Genetic Variation | 1 | 2006 | 926 | 0.050 |
Why?
| | Tonometry, Ocular | 1 | 2000 | 83 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 439 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2000 | 76 | 0.050 |
Why?
| | Muscle Contraction | 2 | 2001 | 413 | 0.050 |
Why?
| | Paleontology | 1 | 2000 | 21 | 0.050 |
Why?
| | Fetal Weight | 1 | 2000 | 51 | 0.050 |
Why?
| | Archaeology | 1 | 2000 | 28 | 0.050 |
Why?
| | Linguistics | 1 | 2000 | 26 | 0.050 |
Why?
| | Geographic Mapping | 1 | 2019 | 21 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2001 | 230 | 0.040 |
Why?
| | Endothelium | 1 | 2000 | 120 | 0.040 |
Why?
| | North America | 1 | 2000 | 266 | 0.040 |
Why?
| | Organ Size | 1 | 2000 | 460 | 0.040 |
Why?
| | Nitroarginine | 1 | 1998 | 48 | 0.040 |
Why?
| | Thiazolidinediones | 1 | 2020 | 146 | 0.040 |
Why?
| | Litter Size | 1 | 1998 | 16 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 257 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1998 | 30 | 0.040 |
Why?
| | Glucagon | 1 | 2018 | 97 | 0.040 |
Why?
| | Cell Division | 1 | 2000 | 776 | 0.040 |
Why?
| | Carotid Sinus | 1 | 1997 | 2 | 0.040 |
Why?
| | Hormones | 1 | 1998 | 135 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1489 | 0.040 |
Why?
| | Adrenal Glands | 1 | 1998 | 72 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 394 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 220 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4077 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1795 | 0.040 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1998 | 146 | 0.040 |
Why?
| | Glomerular Filtration Rate | 2 | 1998 | 683 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 1998 | 380 | 0.040 |
Why?
| | Chemoreceptor Cells | 1 | 1997 | 54 | 0.040 |
Why?
| | Cats | 1 | 1997 | 205 | 0.040 |
Why?
| | Child, Preschool | 2 | 2015 | 9491 | 0.040 |
Why?
| | Genome-Wide Association Study | 2 | 2017 | 1323 | 0.040 |
Why?
| | China | 1 | 1997 | 175 | 0.040 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 368 | 0.040 |
Why?
| | Ferritins | 1 | 2017 | 61 | 0.040 |
Why?
| | Energy Intake | 1 | 2000 | 447 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 565 | 0.040 |
Why?
| | Phosphorylation | 1 | 2021 | 1633 | 0.040 |
Why?
| | Anesthesia | 1 | 1997 | 120 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2020 | 1691 | 0.030 |
Why?
| | California | 1 | 2017 | 382 | 0.030 |
Why?
| | Renin-Angiotensin System | 2 | 2010 | 82 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 2015 | 84 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 827 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2000 | 767 | 0.030 |
Why?
| | Aged | 2 | 2017 | 19657 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 509 | 0.030 |
Why?
| | Latin America | 1 | 2012 | 74 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 539 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 276 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1129 | 0.020 |
Why?
| | Globins | 1 | 2010 | 22 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2010 | 20 | 0.020 |
Why?
| | Thumb | 2 | 2001 | 23 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 167 | 0.020 |
Why?
| | Hydrocortisone | 2 | 2002 | 273 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 755 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 3443 | 0.020 |
Why?
| | Cyclic GMP | 2 | 1998 | 109 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4596 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1670 | 0.020 |
Why?
| | Indians, Central American | 1 | 2007 | 7 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 41 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2871 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3588 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2007 | 321 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6561 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 2851 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 770 | 0.020 |
Why?
| | Heart Failure | 1 | 2017 | 1969 | 0.020 |
Why?
| | Genetic Testing | 1 | 2007 | 389 | 0.020 |
Why?
| | International Cooperation | 1 | 2005 | 177 | 0.020 |
Why?
| | Tilt-Table Test | 1 | 2001 | 7 | 0.010 |
Why?
| | Placebos | 1 | 2001 | 202 | 0.010 |
Why?
| | Societies, Medical | 1 | 2005 | 703 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2001 | 153 | 0.010 |
Why?
| | Water-Electrolyte Balance | 1 | 2000 | 29 | 0.010 |
Why?
| | Transducers, Pressure | 1 | 1999 | 15 | 0.010 |
Why?
| | Fasting | 1 | 2001 | 264 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 268 | 0.010 |
Why?
| | Electrolytes | 1 | 1998 | 59 | 0.010 |
Why?
| | Nitrogen | 1 | 2000 | 154 | 0.010 |
Why?
| | Pregnancy Trimester, First | 1 | 1998 | 126 | 0.010 |
Why?
| | Renin | 1 | 1997 | 35 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 59 | 0.010 |
Why?
| | Aldosterone | 1 | 1997 | 43 | 0.010 |
Why?
| | Bicarbonates | 1 | 1997 | 44 | 0.010 |
Why?
| | Nitrates | 1 | 1997 | 78 | 0.010 |
Why?
| | Nitrites | 1 | 1997 | 81 | 0.010 |
Why?
| | Chlorides | 1 | 1997 | 137 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1997 | 242 | 0.010 |
Why?
| | Sodium | 1 | 1997 | 200 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2000 | 940 | 0.010 |
Why?
| | Body Composition | 1 | 2000 | 653 | 0.010 |
Why?
| | Poverty | 1 | 1999 | 444 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2001 | 1180 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|